Purpose of review For several decades, hematopoietic cell transplantation (HCT) has been considered the standard curative therapy for many patients with hematological malignancies. In addition to the cytotoxic effects of the chemotherapy and radiation used in the conditioning regimen, the benefits of HCT are derived from a reset of the immune system and harnessing the ability of donor T cells to eliminate malignant cells. With the dawn of the era of immunotherapies in the form of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells, the role of HCT has evolved.
INTRODUCTION
The development of immunotherapy in the form of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells has provided new tools for the treatment of hematologic malignancies [1] [2] [3] [4] . These strategies have been embraced with great enthusiasm because of their potential for durable disease control without excessive long-term toxicity, and they are being actively investigated as stand-alone treatments and in combination with other agents or hematopoietic cell transplantation (HCT). In this review, we will explore the evolving role of autologous HCT (autoHCT) and allogeneic HCT (alloHCT) as a complementary platform for novel immunotherapies.
HEMATOPOIETIC CELL TRANSPLANTATION: GENERAL CONCEPTS AND PLATFORM FOR IMMUNOTHERAPY

Autologous hematopoietic cell transplantation
AutoHCT can provide effective salvage therapy for patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin's lymphomas (NHL) [5] [6] [7] , and remains a standard therapy for multiple myeloma [8, 9] . Importantly, not all patients are candidates for autoHCT because of inadequate disease control or comorbidities, and postautoHCT relapse is the most common cause of treatment failure even with the use of maintenance strategies [10, 11] .
Scientific rationale supports the role of autoHCT as an ideal platform for the application of immunotherapy. The early postautoHCT period is characterized by low disease burden as a result of & ]. Moreover, the associated transient lymphodepletion results in elimination of Tregs that may contribute to immune suppression, high levels of homeostatic cytokines that can support natural killer (NK) and T-cell proliferation, and gradual T-cell recovery mediated by homeostatic peripheral expansion of conditioningresistant T cells or T cells reinfused with the graft, which are mainly of effector or memory phenotype [16] [17] [18] [19] [20] [21] . In this unique setting, checkpoint inhibitors may serve to reinvigorate T cells that still exhibit exhaustion phenotype, whereas CAR T cells may exhibit enhanced proliferation and efficacy because of the elimination of Tregs and cytokine sinks [17, 22] .
Allogeneic hematopoietic cell transplantation
Although advances in the selection of recipients and donors, and improvements in the supportive care of transplant recipients have resulted in decreasing transplant-related mortality, relapse after alloHCT remains an important cause of mortality [23] . There is a paucity of acceptable options for patients who relapse after alloHCT, and immunotherapy beyond donor lymphocyte infusion (DLI) is evolving into an option for therapy of relapse after alloHCT. Donor T cells are central players in the immunological effects of alloHCT [24] . In particular, a subset of T cells is alloreactive and can recognize human leukocyte antigen (HLA) that are nonself as foreign [25] . These alloreactive T cells can recognize host cells, including the host-derived cancer cells, and mediate a graft versus tumor (GVT) effect that may eliminate residual disease after HCT and maintain lasting immunosurveillance to prevent relapse [26] . However, a broader and nontumor-specific attack of the host tissue by the alloreactive T cells can also lead to potentially lethal graft versus host disease (GVHD) [25] . Separating GVHD and GVT effects remains one of the holy grails of transplant immunologists. This is of particular relevance to the use of checkpoint inhibitors peri-alloHCT, as potential enhancement of donor-derived T cells with antineoplastic properties that mediate GVT may be accompanied by disinhibition of alloreactive donor T cells and lead to life-threatening GVHD.
Donor lymphocyte infusion
Given the central role of donor T cells in the beneficial and toxic effects of alloHCT, it has been postulated that adoptive transfer of donor T cells at a point after alloHCT could provide beneficial effects like antimicrobial or GVT effects without GVHD [27] [28] [29] . In one of the first reports of this approach, transfusion of donor leukocytes-induced remissions in three patients with of chronic myelogenous leukemia that had relapsed following alloHCT [30] . Two of the three patients remained alive in molecular remission for about two decades, whereas one had a hematological relapse after 20 years and was treated again with DLI after failure with tyrosine kinase inhibitor therapies [31 & ]. This initial success of immunotherapy with DLI led to wider applications of this approach for patients who relapse after alloHCT. In an analysis of 140 patients in US centers, DLI was most successful in patients with relapsed chronic stage chronic myelogenous leukemia and a high percentage of patients attained complete remission [32] . Remissions were also seen in a few patients with multiple myeloma and myelodysplasia, but were far inferior in patients with acute leukemias. Additionally, high incidences of GVHD and pancytopenia were reported. Response was associated with acute and chronic GVHD. In spite of a lack of uniform efficacy and high toxicity, in the absence of alternatives, DLI remains the standard of care for selected patients [33] . As with alloHCT, wider application of DLI is hampered by inability to separate GVHD and GVT effects. However, recent advances in the field of T-cell engineering suggest that such a separation may be feasible in the context of engineered autologous or allogeneic CAR T-cells products, which are characterized by narrow antigen specificity and are devoid of generalized alloreactivity. 
Multiple myeloma
PD-L1 is highly expressed in neoplastic plasma and multiple myeloma stromal cells, whereas T cells of multiple myeloma patients show increased PD-1 Table 1 . Autologous hematopoietic cell transplantation and checkpoint blockade summary points
In phase I and II trials, PD-1 inhibitors have shown high single-agents activity in relapsed or refractory Hodgkin lymphoma and in some subtypes of NHL.
Although scientific rationale supports the notion that peri-autoHCT checkpoint inhibition may lead to enhanced efficacy, high RR have been observed in both transplant-naïve patients and patients receiving PD-1 inhibitors after HCT failure.
CRs with PD-1 inhibitors are infrequent and the available long-term outcome data are sparse; therefore, further research is required to determine the optimal incorporation of anti-PD-1 antibodies in the treatment algorithm and whether such agents may replace autoHCT in the future.
Outside of clinical trials, autoHCT remains the standard therapy for the management of chemosensitive relapsed/refractory Hodgkin lymphoma, NHL, and multiple myeloma, as outlined in the American Society of Blood and Marrow Transplantation guidelines.
autoHCT, autologous hematopoietic cell transplantation; CRs, complete responces; NHL, non-Hodgkin lymphomas; RR, response rates.
expression, suggesting that the PD-1/PD-L1 pathway may play an important role in the immune escape of multiple myeloma [55] [56] [57] [58] and may also lead to development of drug resistance [59 & ]. These observations provide the rationale for evaluating checkpoint blockade in multiple myeloma. Moreover, there is some evidence that the early postautoHCT setting and associated lymphodepletion may be the optimal timing to evaluate the efficacy of anti-PD-1 inhibitors for the treatment of multiple myeloma [17, 58] .
Nivolumab, however, has shown no single agent activity in multiple myeloma [60] . It has been hypothesized that the apparent lack of efficacy of PD-1 inhibition as monotherapy may be because of the immunosuppressive multiple myeloma microenvironment [61] , or because immunosenescence rather than exhaustion is the mechanism responsible for T-cell dysfunction in multiple myeloma [62 && ]. However, it has also been shown that exhausted/senescent T cells of multiple myeloma patients may be revived with PD-1 blockade [17] . Moreover, immunomodulatory agents, such as lenalidomide, may have potentiating effects in the antimultiple myeloma immune responses elicited by anti-PD-1-antibodies [57, 63] . Notably, in a phase II trial, pembrolizumab in combination with pomalidomide and dexamethasone was associated with durable responses in 60% of 48 patients with refractory or relapsed multiple myeloma [64 && ]. However, the recent halts on studies with pembrolizumab in multiple myeloma because of unacceptable toxicities have tempered the enthusiasm for the use of these combinations in multiple myeloma and more information about the nature of these side-effects is awaited.
CHECKPOINT INHIBITION AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
There is a shared goal of alloHCT and immune checkpoint inhibition in the generation of antitumor immunity through polyclonal-activated T cells.
In alloHCT, antitumor immunity is mediated by allogeneic T cells that can recognize host antigens on malignant cells. Relapse after alloHCT is associated with donor T cells that become dysfunctional because of exhaustion and can be reinvirogated by PD-1/PD-L1 and CTLA-4 blocking antibodies [65] . Evidence from preclinical mouse experiments suggests that immune checkpoint blockade can activate GVT-inducing allogeneic T cells [66,67 & ] ( Table 2) .
Cytotoxic T-lymphocyte-associated protein-4 inhibition
The anti-CTLA antibody ipilimumab was tested in patients with relapse after alloHCT. An initial trial in 29 patients revealed a favorable toxicity profile of a single infusion of ipilimumab at doses up to 3 mg/ kg, and no severe GVHD was observed [68] . CR of Hodgkin lymphoma in two patients and partial remission of mantle cell lymphoma in one patient were observed. A follow-up multicenter trial in 28 patients used multiple doses of ipilimumab (3 mg/kg or 10 mg/kg) [69 && ]. Five CRs were observed in the 22 patients receiving a dose of 10 mg/kg, including four patients with extramedullary acute myeloid leukemia (AML) and one with myelodysplastic syndromes transforming into AML. However, at this dose substantial toxicity was observed, including grade 3 GVHD, two severe immune-related adverse events and one death from GVHD with colitis and pneumonitis.
PD-1 inhibition
Checkpoint inhibition with anti-PD-1 antibodies has been reported in two retrospective studies of patients with relapsed lymphoma after alloHCT. In the first study, 20 patients with relapsed Hodgkin lymphoma after alloHCT treated with nivolumab [70 & ]. Overall response rates were 95%, but substantial GVHD was observed in six patients (30%), of whom one succumbed to GVHD. In the second study of 31 patients (Hodgkin lymphoma ¼ 29, NHL ¼ 2) from 10 US centers who underwent treatment with PD-1 inhibitors Table 2 . Allogeneic hematopoietic cell transplantation and checkpoint blockade summary points Checkpoint blockade in the form of anti-CTLA-4 or anti-PD-1 antibodies for relapsed hematologic malignancies has shown efficacy after alloHCT; however, it is complicated by potentially life-threatening toxicity including GVHD and immune-mediated side-effects Administration of checkpoint blockade prior to alloHCT has been associated with higher rates of severe GVHD postalloHCT Administration of checkpoint inhibitors after alloHCT should be carefully assessed outside the context of a clinical trial, and prior exposure to checkpoint inhibitors should be taken into consideration for patients proceeding to alloHCT Further research is required to determine how to safely incorporate checkpoint inhibitors in alloHCT platforms, and how to identify patients that may benefit from such interventions.
GVHD, graft versus host disease; alloHCT, allogeneric hematopoietic cell transplantation.
after alloHCT, the overall response was about 78% at a median of 1.2-year follow-up [71 && ]. However, considerable GVHD was observed, including newly emergent GVHD in 17 (55%) of the patients and 8 (26%) succumbed to GVHD. Checkpoint inhibition with nivolumab has also been explored in AML. In a case series of three patients with AML who relapsed after alloHCT, nivolumab led to three distinct responses: one CR, one disease stabilization, and one nonresponse. Pancytopenia and skin GVHD were the only substantial toxicities [72] .
The above studies highlight the considerable risks associated with the reinvigoration of GVHDcausing alloreactive T cells with checkpoint inhibition after alloHCT. Although checkpoint inhibition has potential effectiveness after alloHCT, further studies are critical to understand which patient populations are more likely to benefit from checkpoint inhibition and the optimal time and dose of treatment to subside the risk of GVHD.
Prior PD-1 inhibition with subsequent allogeneic hematopoietic cell transplantation
With a growing use of immune checkpoint inhibitors in treating lymphomas, increasing numbers of patients referred for alloHCT have previously received therapy with PD-1 blockers. In an international retrospective study of 39 patients (Hodgkin lymphoma ¼ 31, NHL ¼ 7) treated with an anti-PD1 antibody at some point prior to alloHCT, 38 underwent T-cell replete reduced intensity conditioning and lower than expected relapse rates were observed. [73 && ]. Importantly, although the overall incidences of GVHD were similar to historical controls, the incidence of severe GVHD was substantially higher, and was lethal in three patients. Furthermore, prior anti-PD1 treatment did not seem to influence T-cell reconstitution but showed a decreased regulatory T cell to conventional T-cell ratio. A smaller study of nine Hodgkin lymphoma patients who received nivolumab as a bridge to alloHCT also reported GVHD in all the patients [74 & ]. These studies suggest a legacy effect of immune checkpoint inhibitors that can reinvigorate allogeneic donor T cells after alloHCT.
Chimeric antigen receptor T-cell therapy and hematopoietic cell transplantation
AlloHCT and DLI represent the archetypical and most established form of cell therapy in hematological malignancies. However, in recent years, the field of cell therapy has undergone a revolution with the advent of CAR T cells. A CAR is a synthetic fusion protein consisting of the variable portion of an antibody, known as a single-chain variable fragment that can target an antigen displayed on the surface of a tumor cell, linked to a transmembrane domain T-cell receptor (TCR) cluster of differentiation (CD)3-zeta chain, and most commonly costimulatory signaling domains from CD28 or 4-1BB [75] . The synthetic gene is introduced in the T cell using retroviral or lentiviral vectors that ensure genetic integration and constitutive expression ( Table 3) .
The best studied CAR T cells have been those directed against CD19, a 95 kD transmembrane glycoprotein that is normally expressed on mature and precursor B cells [76] . It is also expressed on B-cell malignancies, including B-cell acute lymphocytic leukemia (B-ALL), CLL, and NHL [77 && ]. Although the expression of CD19 is not exclusive to malignant cells, the elimination of normal B cells is compatible with life, making CD19 a suitable target for B-cell malignancies.
The first generation of CAR constructs consisted of the single-chain variable fragment linked to a functional CD3z intracellular signaling domain [78] . Although this initial design was functional [79] , effective T-cell proliferation and expansion was achieved after the addition of a second-signal transmembrane costimulatory domains that gave rise to the second generation design. Autologous CD19 CAR T cells have been used in relapsed B-ALL with excellent RR using both CD28 [80] [81] [82] [83] or 4-1BB costimulation [84 & ]. CAR T cells have been studied in relapsed/refractory settings, typically in patients who were refractory to chemotherapy or had relapsed after autologous or alloHCT. Table 3 . Chimeric antigen receptor T cells and hematopoietic cell transplantation summary points CD19 CAR T-cell therapy is a powerful new treatment options for relapsed/refractor B-cell malignancies that can be administered along with autoHCT.
AlloHCT is a reasonable option for eligible patients who are treated with autologous CD19 CAR T cells for aggressive and intractable B-cell malignancies.
Adoptively transferred donor CD19 CAR T cells is a viable option to treat patients for relapse after alloHCT.
FDA Approval of CD19 CAR T cells for pediatric ALL and adult non-Hodgkin lymphomas is expected in the coming months.
alloHCT, allogeneic hematopoietic cell transplantation; autoHCT, autologous hematopoietic cell transplantation; CAR, chimeric antigen receptor.
Chimeric antigen receptor T cells and autologous hematopoietic cell transplantation
An intense lymphodepleting regimen associated with autoHCT can provide an excellent platform for adoptive T-cell therapy [85] . In the first trial of CD19 CAR T cells in NHL, two patients with DLBCL received adoptively transferred T cells using first generation construct 1 month after autoHCT, and one of the two patients remained without evidence of disease 9 years later [79] . In subsequent trials for lymphoma and CLL, patients received a less intense lymphodepleting regimen, thus alleviating the requirement of stem cell rescue prior to adoptive transfer [86] . Of the 15 patients, including nine DLBCL, two indolent lymphomas, and four CLL, eight had a CR and four a partial remission. With more optimized manufacturing of CD19 CAR T cells and adoptive transfer at day 2 postautoHCT, encouraging RR were achieved [87] .
More recently, investigators at memorial sloan kettering cancer center (MSKCC) performed a pilot trial of CD19 CAR T cells postautoHCT for poor risk and aggressive B-cell NHL (B-NHL) (NCT01840566). In a preliminary report, the first dose level induced a CR in four of 15 patients [88 & ]. At a median followup for survivors of 31 months, the 2-year progression-free survival was 30% (95% confidence interval: 20-70%) in this high-risk population. Given the expected approval of CD19 CAR T cells in patients with DLBCL who are refractory to standard therapy or have relapsed after autoHCT, it is expected that future studies will more closely assess whether CD19 CAR T-cell therapies can replace autoHCT entirely in NHL.
Chimeric antigen receptor T cells and allogeneic hematopoietic cell transplantation
Historically, B-ALL in adults has been a poor prognosis disease and patients with relapsed B-ALL have few options of salvage treatment [89] . In an initial report of five patients with relapsed B-ALL treated with CD19 CAR T cells after high-dose cyclophosphamide at MSKCC, minimal residual disease (MRD)-negative CR was achieved in all patients, leading to a successful transition to alloHCT [80] . Subsequently, the same group reported data in 16-adult patients with relapsed or refractory B-ALL and showed that MRD À CR was achieved in 13 of the patients, and seven of the 16 (44%) proceeded alloHCT [81] . These results are superior to historical controls where salvage therapy could lead to transplant in a minority of patients. Thus, CD19 CAR T cells have been shown to be an effective induction agent and bridge to alloHCT [89] . In another study, 30 patients with relapsed/refractory B-ALL included 18 patients with relapsed disease after alloHCT, and 27 patients achieved a CR [82] . In patients who were ineligible for subsequent transplant, sustained B-cell aplasia and detectable CAR T cells were observed, suggesting that, in B-ALL, CD19 CAR T cells can be curative in some patients without a subsequent alloHCT. However, relapses especially with CD19-negative variants have been observed and alloHCT remains an option to induce maximal depth of remission and increase the possibility of cure after CD19 CAR T-cell therapy.
Donor CD19 chimeric antigen receptor T cells
CAR T cells are unique in their ability to inducespecific cytolysis of targets without the requirement for presentation of target peptides in the context of HLA. In the setting of alloHCT, this is an important advantage as the T cells can function and mediatespecific killing in HLA-mismatched donor-recipient combinations. Indeed in the phase I trial conducted at MSKCC, four patients were treated after alloHCT relapse with patient-derived 'autologous' CD19 CAR T cells that were of donor origin. Two of the treated patients achieved MRD À CR and one had a response with MRD þ disease. Despite responses, there was no clinical evidence of GVHD. Similar absence of GVHD was also reported in a patient with adult B-ALL with extramedullary leukemia who received autologous CD19 CAR T cells of donor origin [90] .
The lack of GVHD elicited by donor CD19 CAR T cells is intriguing. Donor-derived T cells expressing CD19 CAR can potentially be activated through either the CAR by CD19-target recognition or through the endogenous TCR. It is estimated that about 5-10% of endogenous TCRs can recognize a nonself HLA and hence are alloreactive. These alloreactive T cells are the chief mediators of GVHD. In a mouse model, it has been suggested that recognition of CD19 þ leukemia cells by CD19 CAR T cells promotes an inflammatory response with features of lethal GVHD [91 & ]. Thus, in selected genetic backgrounds, alloreactive T cells expressing CD19 CAR T cells may exhibit enhanced activation through CAR activation by CD19 expressing leukemic B cells.
In addition to the two above observations, several clinical studies have shown decreased GVHD mediated by donor T cells expressing a functional CAR. In two reports including 20 patients treated with allogeneic CD19 CAR T cells, 14 of 20 patients had demonstrated prior GVHD and yet did not develop recurrence of GVHD with CD19 CAR T-cell infusion [92,93 && ]. In all, 30 patients have been reported who have been treated with allogeneic donor CD19 CAR T cells in the posttransplant setting with only two patients exhibiting GVHD [90,92,93 && ,94] . Notably, these studies included patients with active B-cell malignancies present at the time of T-cell infusion. We investigated this observation in mouse models and found that alloreactive T cells undergo cumulative hyperactivation, and functional exhaustion and deletion in response to persistent signaling through both endogenous (alloreactive) TCRs and (CD19-reactive) CAR [95 && ]. The nonalloreactive CD19 CAR T cells undergo normal activation and maintain anti-CD19-immunity leading to tumor clearance. The exhaustion and deletion of alloreactive CD19 CAR T cells is lost when the CD28 constimulation domain in the CAR construct is replaced by 4-1BB costimulation that results in amelioration of exhaustion [96] .
The option of donor CD19 CAR T cells for patients who relapse after alloHCT is of great importance as these patients are less likely to have sufficient healthy T cells for CAR T-cell generation. Further research into the dynamic interactions between endogenous TCR and CAR is important to design strategies whereby the risk of GVHD is decreased while maintaining the antitumor efficacy of CAR T cells.
Off the shelf chimeric antigen receptor T cells
Manufacturing of individualized CAR T-cells hampers its wider application. Furthermore, both autologous and allogeneic CAR T cell manufacturing is onerous and fails to produce adequate numbers of CAR T cells in a number of patients. Development of a universal donor-derived off the shelf CAR T cells that can be applied across HLA barriers could overcome these limitations [97] .
In animal models, it has been shown that in-vitro generated precursor T cells undergo thymic education in the host upon adoptive transfer leading to the development of tolerance and no GVHD [98] . These precursor T cells can in theory be obtained from a nonhost, nondonor third party universal donor, and transduced with a CD19 CAR for tumor-specific activity [99] . The development of NOTCH-based OP9-DL1 culture system for generation of precursor T cells has been adapted for use in humans and umbilical cord blood-derived precursor T cells can now be generated in vitro [100 & ]. This has raised the possibilities of generation of off the shelf CAR T cells for clinical use in the near future.
CONCLUSION
In summary, checkpoint inhibitors and adoptive T-cell therapies are being integrated into autologous and alloHCT platforms in hematological malignancies, and is some instances, may replace HCT. In many settings, these approaches can be complementary and lead to effective and durable antitumor effects. However, toxicities because of uncontrolled T-cell activation can cause serious and potentially fatal deathly complications. Further research into the strategies to limit toxicities without affecting antitumor immunity is of critical importance. Acknowledgements A.G., I.P., and M-A.P. contributed to the conception and design of the work and wrote the manuscript. 52.
